From Wikipedia, the free encyclopedia
FGI-106 Legal status
N 1 ,N 7 -bis[3-(dimethylamino)propyl]-3,9-dimethylquinolino[8,7-h ]quinoline-1,7-diamine
CAS Number PubChem CID ChemSpider UNII CompTox Dashboard (EPA ) Formula C 28 H 38 N 6 Molar mass 458.640 g·mol−1 3D model (JSmol )
CN(C)CCCNc(c2ccc14)cc(C)nc2c1ccc3c4nc(C)cc3NCCCN(C)C
InChI=1S/C28H38N6/c1-19-17-25(29-13-7-15-33(3)4)23-11-10-22-21(27(23)31-19)9-12-24-26(18-20(2)32-28(22)24)30-14-8-16-34(5)6/h9-12,17-18H,7-8,13-16H2,1-6H3,(H,29,31)(H,30,32)
Key:WJUPENLNVUCETH-UHFFFAOYSA-N
FGI-106 is a broad-spectrum antiviral drug developed as a potential treatment for enveloped RNA viruses, in particular viral hemorrhagic fevers from the bunyavirus , flavivirus and filovirus families. It acts as an inhibitor which blocks viral entry into host cells. In animal tests FGI-106 shows both prophylactic and curative action against a range of deadly viruses for which few existing treatments are available, including the bunyaviruses hantavirus , Rift Valley fever virus and Crimean-Congo hemorrhagic fever virus , the flavivirus dengue virus , and the filoviruses Ebola virus and Marburg virus .[ 1] [ 2] [ 3] [ 4] [ 5]
See also
References
^ Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, et al. (September 2009). "Development of a broad-spectrum antiviral with activity against Ebola virus". Antiviral Research . 83 (3): 245–51. doi :10.1016/j.antiviral.2009.06.001 . PMID 19523489 . ^ Smith DR, Ogg M, Garrison A, Yunus A, Honko A, Johnson J, Olinger G, Hensley LE, Kinch MS (2010). "Development of FGI-106 as a broad-spectrum therapeutic with activity against members of the family Bunyaviridae" . Virus Adaptation and Treatment : 9. doi :10.2147/VAAT.S6903 ^ Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, et al. (April 2011). "Identification of a small-molecule entry inhibitor for filoviruses" . Journal of Virology . 85 (7): 3106–19. doi :10.1128/JVI.01456-10 . PMC 3067866 PMID 21270170 . ^ Ippolito G, Feldmann H, Lanini S, Vairo F, Di Caro A, Capobianchi MR, Nicastri E (March 2012). "Viral hemorrhagic fevers: advancing the level of treatment" . BMC Medicine . 10 : 31. doi :10.1186/1741-7015-10-31 . PMC 3325866 PMID 22458265 . {{cite journal }}: CS1 maint: unflagged free DOI (link )^ Picazo E, Giordanetto F (February 2015). "Small molecule inhibitors of ebola virus infection". Drug Discovery Today . 20 (2): 277–86. doi :10.1016/j.drudis.2014.12.010 . PMID 25532798 .
